MYCOBOON-500 TAB
MRP: 7,830
Packaging: 10 x 10
Pack Type: tablet
Composition:
Mycophenolate Mofetil 500MG
Indication:
used to prevent organ rejection in patients undergoing kidney, heart, or liver transplants. It works by suppressing the immune system to prevent it from attacking the transplanted organ
Description:
Mycophenolate Mofetil (MMF) 500 mg is a potent immunosuppressive agent used primarily for the prevention of organ rejection in patients who have undergone kidney, heart, or liver transplantation. It acts as a prodrug of mycophenolic acid (MPA), which inhibits inosine monophosphate dehydrogenase (IMPDH)—an enzyme necessary for the proliferation of T and B lymphocytes.
This mechanism helps suppress the immune system's response to the transplanted organ, reducing the likelihood of rejection when used alongside other agents like cyclosporine and corticosteroids.
Tags:
- Prevents acute and chronic organ rejection
- Reduces the need for high-dose corticosteroids
- Effective in long-term immunosuppressive regimens
- Targets lymphocyte proliferation specifically
- Used in kidney, heart, and liver transplant recipients
Usage Information
Dosage
Adults (Kidney Transplant): 1,000 mg to 1,500 mg twice daily (total 2,000–3,000 mg/day) Administer on an empty stomach when possible to improve absorption Swallow tablets whole—do not crush or split Adjust dosage based on clinical response, body weight, and co-administered drugs Use only under supervision of a specialist in transplant medicine.
Side Effects
Common: Diarrhea, nausea, vomiting, infections (UTI, respiratory) Hematologic: Leukopenia, anemia, thrombocytopenia Serious: Risk of lymphoma, skin cancer, progressive multifocal leukoencephalopathy (PML) Teratogenic: High risk of birth defects and miscarriage
Contraindications
Pregnancy or women not using effective contraception Known allergy to MMF or MPA Patients with severe active infections Not recommended in patients with rare hereditary enzyme deficiencies (e.g., HGPRT deficiency)